TIE1 and retinal disorder: Therefore, AKB-9778 is currently undergoing phase II clinical trials as a therapeutic treatment for retinal vascular diseases characterized by angiopoietin–Tie axis dysregulation such as diabetic macular edema and retinopathy (Campochiaro et al, 2016) and diabetic hypertension (Siragusa et al, 2021).